Hao Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hao Xiong has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Cunyi Fan
Department of Orthopedics, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
6 shared publications - Weixuan Liu
Department of Sports Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, China
4 shared publications - Shiyang Yu
Department of Orthopaedics, Shanghai Sixth People’s Hospital, Shanghai, China
3 shared publications - Yi Xu
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Ziyang Sun
Department of Orthopedics, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, PR China
3 shared publications - Wei Wang
Department of Orthopedics, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
2 shared publications
Latest Publications
- 26 December 2025
- Published by Springer Nature in MedScience
- Vol. 19 (6) , 911-932
Current state of bioceramic bone repair materials in immune regulation: a review
Extensive bone defects represent a significant clinical challenge, often leading to severe impairment of patients function and quality of life. Traditional treatments, such as autografts and allografts, are widely used but have notable limitations, including donor site morbidity and immunogenicity. As a result, tissue engineering has attracted increasing attention as a viable alternative. Bioceramic bone repair materials provide both mechanical support and bioactive functions in the treatment of bone defects. They modulate the immune microenvironment to promote cellular behaviors and signaling pathways conducive to bone regeneration. The immunoregulatory effects of these materials play a critical role throughout the bone repair process and are pivotal in determining the success of regeneration. For instance, hydroxyapatite can induce the polarization of macrophages towards the M2 phenotype, exerting anti-inflammatory effects that promote bone tissue repair. This review summarizes recent advancements in the research of bioceramics for bone tissue engineering, with a focus on the classification of bioceramic materials, their immunomodulatory mechanisms in bone regeneration, current fabrication techniques, and the status of clinical translation. We aim to provide insights that support future research and the development of improved strategies for bone defect repair.
- 26 December 2025
- Published by Springer Nature in MedScience
- Vol. 19 (6) , 911-932
Current state of bioceramic bone repair materials in immune regulation: a review
Extensive bone defects represent a significant clinical challenge, often leading to severe impairment of patients function and quality of life. Traditional treatments, such as autografts and allografts, are widely used but have notable limitations, including donor site morbidity and immunogenicity. As a result, tissue engineering has attracted increasing attention as a viable alternative. Bioceramic bone repair materials provide both mechanical support and bioactive functions in the treatment of bone defects. They modulate the immune microenvironment to promote cellular behaviors and signaling pathways conducive to bone regeneration. The immunoregulatory effects of these materials play a critical role throughout the bone repair process and are pivotal in determining the success of regeneration. For instance, hydroxyapatite can induce the polarization of macrophages towards the M2 phenotype, exerting anti-inflammatory effects that promote bone tissue repair. This review summarizes recent advancements in the research of bioceramics for bone tissue engineering, with a focus on the classification of bioceramic materials, their immunomodulatory mechanisms in bone regeneration, current fabrication techniques, and the status of clinical translation. We aim to provide insights that support future research and the development of improved strategies for bone defect repair.
- Open Access
- 21 August 2025
- Published by Elsevier in Materials & Design
- Vol. 258
Folate-modified nanodelivery platform loaded with triptolide for targeted synergistic photothermal therapy of macrophages to alleviate rheumatoid arthritis
- 21 August 2025
- Published by Elsevier in Materials & Design
- Vol. 258
Open AccessFolate-modified nanodelivery platform loaded with triptolide for targeted synergistic photothermal therapy of macrophages to alleviate rheumatoid arthritis
- 3 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70314
Inflammatory Bowel Disease and Risk of Rheumatoid Arthritis: A UK Biobank Cohort Study
Objectives: Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are both prevalent inflammatory conditions within the population. Our objective was to explore the relationship between IBD and RA, while examining the role of inflammatory mediators in the observed association. Methods: We used data from the UK Biobank, a population‐based prospective cohort study that recruited adults aged 37–73 years from 22 centers in England, Scotland, and Wales between 2006 and 2010. We included patients diagnosed with IBD at baseline and excluded those with RA at baseline or missing follow‐up information. Cox regression proportional hazard models were employed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) between patients with IBD (Ulcerative colitis and Crohn's disease) at baseline and the risk of RA. Additionally, we conducted mediation analysis to examine the roles of C‐reactive protein (CRP) and several composite inflammatory indices as potential mediators. Results: After excluding participants with RA at baseline ( N = 6769), those lacking IBD subtype information ( N = 475), and those with missing covariate data ( N = 121 195), a total of 373 693 individuals were included in the analysis. Compared with individuals without IBD, those with IBD had a significantly higher risk of developing RA (hazard ratio 2.06, 95% confidence interval 1.69–2.51). This association remained robust after adjustment for multiple confounders and across all major subgroups. Notably, the risk of RA associated with IBD was even higher among individuals with a low polygenic risk score for RA. Mediation analysis showed that systemic inflammatory markers, such as CRP, explained only a modest proportion of the association between IBD and RA, with the highest mediation proportion observed being 9.56%. Conclusion: In the UK Biobank cohort study, individuals with IBD demonstrated an increased risk of developing RA. Future research should aim to gain insight into these underlying mechanisms and explore ways to improve long‐term health outcomes in these patients.
- 3 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70314
Inflammatory Bowel Disease and Risk of Rheumatoid Arthritis: A UK Biobank Cohort Study
Objectives: Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are both prevalent inflammatory conditions within the population. Our objective was to explore the relationship between IBD and RA, while examining the role of inflammatory mediators in the observed association. Methods: We used data from the UK Biobank, a population‐based prospective cohort study that recruited adults aged 37–73 years from 22 centers in England, Scotland, and Wales between 2006 and 2010. We included patients diagnosed with IBD at baseline and excluded those with RA at baseline or missing follow‐up information. Cox regression proportional hazard models were employed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) between patients with IBD (Ulcerative colitis and Crohn's disease) at baseline and the risk of RA. Additionally, we conducted mediation analysis to examine the roles of C‐reactive protein (CRP) and several composite inflammatory indices as potential mediators. Results: After excluding participants with RA at baseline ( N = 6769), those lacking IBD subtype information ( N = 475), and those with missing covariate data ( N = 121 195), a total of 373 693 individuals were included in the analysis. Compared with individuals without IBD, those with IBD had a significantly higher risk of developing RA (hazard ratio 2.06, 95% confidence interval 1.69–2.51). This association remained robust after adjustment for multiple confounders and across all major subgroups. Notably, the risk of RA associated with IBD was even higher among individuals with a low polygenic risk score for RA. Mediation analysis showed that systemic inflammatory markers, such as CRP, explained only a modest proportion of the association between IBD and RA, with the highest mediation proportion observed being 9.56%. Conclusion: In the UK Biobank cohort study, individuals with IBD demonstrated an increased risk of developing RA. Future research should aim to gain insight into these underlying mechanisms and explore ways to improve long‐term health outcomes in these patients.
- 12 December 2023
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (5) , 389-396
Development and Validation of a Deep-Learning Model to Predict Total Hip Replacement on Radiographs
Background: There are few methods for accurately assessing the risk of total hip arthroplasty (THA) in patients with osteoarthritis. A novel and reliable method that could play a substantial role in research and clinical routine should be investigated. The purpose of the present study was to develop a deep-learning model that can reliably predict the risk of THA with use of radiographic images and clinical symptom data. Methods: This retrospective, multicenter, case-control study assessed hip joints on weighted-bearing anteroposterior pelvic radiographs obtained from Osteoarthritis Initiative (OAI) participants. Participants who underwent THA were matched to controls according to age, sex, body mass index, and ethnicity. Cases and controls were uniformly split into training, validation, and testing data sets at proportions of 72% (n = 528), 14% (n = 104), and 14% (n = 104), respectively. Images and clinical symptom data were passed through a detection model and a deep convolutional neural network (DCNN) model to predict the probability of THA within 9 years as well as the most likely time period for THA (0 to 2 years, 3 to 5 years, 6 to 9 years). Model performance was assessed with use of the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity in the testing set. Results: A total of 736 participants were evaluated, including 184 cases and 552 controls. The prediction model achieved an overall accuracy, sensitivity, and specificity of 91.35%, 92.59% and 86.96%, respectively, with an AUC of 0.944, for THA within 9 years. The AUC of the DCNN model for assessing the most likely time period was 0.907 for 0 to 2 years, 0.916 for 3 to 5 years, and 0.841 for 6 to 9 years. Gradient-weighted class activation mapping closely corresponded to regions affecting the prediction of the DCNN model. Conclusions: The proposed DCNN model is a reliable and valid method to predict the probability of THA—within limitations. It could assist clinicians in patient counseling and decision-making regarding the timing of the intervention. In the future, by increasing the size of the data set, enhancing the ethnic and socioeconomic diversity of the participants, and improving the follow-up rate, the quality of the conclusions can be further improved. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 12 December 2023
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (5) , 389-396
Development and Validation of a Deep-Learning Model to Predict Total Hip Replacement on Radiographs
Background: There are few methods for accurately assessing the risk of total hip arthroplasty (THA) in patients with osteoarthritis. A novel and reliable method that could play a substantial role in research and clinical routine should be investigated. The purpose of the present study was to develop a deep-learning model that can reliably predict the risk of THA with use of radiographic images and clinical symptom data. Methods: This retrospective, multicenter, case-control study assessed hip joints on weighted-bearing anteroposterior pelvic radiographs obtained from Osteoarthritis Initiative (OAI) participants. Participants who underwent THA were matched to controls according to age, sex, body mass index, and ethnicity. Cases and controls were uniformly split into training, validation, and testing data sets at proportions of 72% (n = 528), 14% (n = 104), and 14% (n = 104), respectively. Images and clinical symptom data were passed through a detection model and a deep convolutional neural network (DCNN) model to predict the probability of THA within 9 years as well as the most likely time period for THA (0 to 2 years, 3 to 5 years, 6 to 9 years). Model performance was assessed with use of the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity in the testing set. Results: A total of 736 participants were evaluated, including 184 cases and 552 controls. The prediction model achieved an overall accuracy, sensitivity, and specificity of 91.35%, 92.59% and 86.96%, respectively, with an AUC of 0.944, for THA within 9 years. The AUC of the DCNN model for assessing the most likely time period was 0.907 for 0 to 2 years, 0.916 for 3 to 5 years, and 0.841 for 6 to 9 years. Gradient-weighted class activation mapping closely corresponded to regions affecting the prediction of the DCNN model. Conclusions: The proposed DCNN model is a reliable and valid method to predict the probability of THA—within limitations. It could assist clinicians in patient counseling and decision-making regarding the timing of the intervention. In the future, by increasing the size of the data set, enhancing the ethnic and socioeconomic diversity of the participants, and improving the follow-up rate, the quality of the conclusions can be further improved. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
- Top Cited PapersOpen Access
- 1 December 2023
- Published by KEAI Publishing in Bioactive Materials
- Vol. 30, 169-183
Dual-engineered cartilage-targeting extracellular vesicles derived from mesenchymal stem cells enhance osteoarthritis treatment via miR-223/NLRP3/pyroptosis axis: Toward a precision therapy
Osteoarthritis (OA) is the most common disabling joint disease with no effective disease modifying drugs. Extracellular vesicles released by several types of mesenchymal stem cells could promote cartilage repair and ameliorate OA pathology in animal models, representing a novel therapeutic strategy. In this study, we demonstrated that extracellular vesicles derived from human umbilical cord mesenchymal stem cells (hUC-EVs) could maintain chondrocyte homeostasis and alleviate OA, and further revealed a novel molecular mechanism of this therapeutic effect. miR-223, which could directly bind with the 3'UTR of NLRP3 mRNA, was found to be a key miRNA for hUC-EVs to exert beneficial effects on inflammation inhibiting and cartilage protecting. For enhancing the effect on mitigating osteoarthritis, exogenous miR-223 was loaded into hUC-EVs by electroporation, and a collagen II-targeting peptide (WYRGRL) was modified onto the surface of hUC-EVs by genetic engineering to achieve a more targeted and efficient RNA delivery to the cartilage. The dual-engineered EVs showed a maximal effect on inhibiting the NLRP3 inflammasome activation and chondrocyte pyroptosis, and offered excellent results for the treatment of OA. This study provides a novel theoretical basis and a promising therapeutic strategy for the application of engineered extracellular vesicles in OA treatment.
- 1 December 2023
- Published by KEAI Publishing in Bioactive Materials
- Vol. 30, 169-183
Top Cited PapersOpen AccessDual-engineered cartilage-targeting extracellular vesicles derived from mesenchymal stem cells enhance osteoarthritis treatment via miR-223/NLRP3/pyroptosis axis: Toward a precision therapy
Osteoarthritis (OA) is the most common disabling joint disease with no effective disease modifying drugs. Extracellular vesicles released by several types of mesenchymal stem cells could promote cartilage repair and ameliorate OA pathology in animal models, representing a novel therapeutic strategy. In this study, we demonstrated that extracellular vesicles derived from human umbilical cord mesenchymal stem cells (hUC-EVs) could maintain chondrocyte homeostasis and alleviate OA, and further revealed a novel molecular mechanism of this therapeutic effect. miR-223, which could directly bind with the 3'UTR of NLRP3 mRNA, was found to be a key miRNA for hUC-EVs to exert beneficial effects on inflammation inhibiting and cartilage protecting. For enhancing the effect on mitigating osteoarthritis, exogenous miR-223 was loaded into hUC-EVs by electroporation, and a collagen II-targeting peptide (WYRGRL) was modified onto the surface of hUC-EVs by genetic engineering to achieve a more targeted and efficient RNA delivery to the cartilage. The dual-engineered EVs showed a maximal effect on inhibiting the NLRP3 inflammasome activation and chondrocyte pyroptosis, and offered excellent results for the treatment of OA. This study provides a novel theoretical basis and a promising therapeutic strategy for the application of engineered extracellular vesicles in OA treatment.
- Open Access
Multifunctional Extracellular Matrix Hydrogel with Self-Healing Properties and Promoting Angiogenesis as an Immunoregulation Platform for Diabetic Wound Healing
Treating chronic wounds is a global challenge. In diabetes mellitus cases, long-time and excess inflammatory responses at the injury site may delay the healing of intractable wounds. Macrophage polarization (M1/M2 types) can be closely associated with inflammatory factor generation during wound healing. Quercetin (QCT) is an efficient agent against oxidation and fibrosis that promotes wound healing. It can also inhibit inflammatory responses by regulating M1-to-M2 macrophage polarization. However, its limited solubility, low bioavailability, and hydrophobicity are the main issues restricting its applicability in wound healing. The small intestinal submucosa (SIS) has also been widely studied for treating acute/chronic wounds. It is also being extensively researched as a suitable carrier for tissue regeneration. As an extracellular matrix, SIS can support angiogenesis, cell migration, and proliferation, offering growth factors involved in tissue formation signaling and assisting wound healing. We developed a series of promising biosafe novel diabetic wound repair hydrogel wound dressings with several effects, including self-healing properties, water absorption, and immunomodulatory effects. A full-thickness wound diabetic rat model was constructed for in vivo assessment of QCT@SIS hydrogel, in which hydrogels achieved a markedly increased wound repair rate. Their effect was determined by the promotion of the wound healing process, the thickness of granulation tissue, vascularization, and macrophage polarization during wound healing. At the same time, we injected the hydrogel subcutaneously into healthy rats to perform histological analyses of sections of the heart, spleen, liver, kidney, and lung. We then tested the biochemical index levels in serum to determine the biological safety of the QCT@SIS hydrogel. In this study, the developed SIS showed convergence of biological, mechanical, and wound-healing capabilities. Here, we focused on constructing a self-healing, water-absorbable, immunomodulatory, and biocompatible hydrogel as a synergistic treatment paradigm for diabetic wounds by gelling the SIS and loading QCT for slow drug release.
Open AccessMultifunctional Extracellular Matrix Hydrogel with Self-Healing Properties and Promoting Angiogenesis as an Immunoregulation Platform for Diabetic Wound Healing
Treating chronic wounds is a global challenge. In diabetes mellitus cases, long-time and excess inflammatory responses at the injury site may delay the healing of intractable wounds. Macrophage polarization (M1/M2 types) can be closely associated with inflammatory factor generation during wound healing. Quercetin (QCT) is an efficient agent against oxidation and fibrosis that promotes wound healing. It can also inhibit inflammatory responses by regulating M1-to-M2 macrophage polarization. However, its limited solubility, low bioavailability, and hydrophobicity are the main issues restricting its applicability in wound healing. The small intestinal submucosa (SIS) has also been widely studied for treating acute/chronic wounds. It is also being extensively researched as a suitable carrier for tissue regeneration. As an extracellular matrix, SIS can support angiogenesis, cell migration, and proliferation, offering growth factors involved in tissue formation signaling and assisting wound healing. We developed a series of promising biosafe novel diabetic wound repair hydrogel wound dressings with several effects, including self-healing properties, water absorption, and immunomodulatory effects. A full-thickness wound diabetic rat model was constructed for in vivo assessment of QCT@SIS hydrogel, in which hydrogels achieved a markedly increased wound repair rate. Their effect was determined by the promotion of the wound healing process, the thickness of granulation tissue, vascularization, and macrophage polarization during wound healing. At the same time, we injected the hydrogel subcutaneously into healthy rats to perform histological analyses of sections of the heart, spleen, liver, kidney, and lung. We then tested the biochemical index levels in serum to determine the biological safety of the QCT@SIS hydrogel. In this study, the developed SIS showed convergence of biological, mechanical, and wound-healing capabilities. Here, we focused on constructing a self-healing, water-absorbable, immunomodulatory, and biocompatible hydrogel as a synergistic treatment paradigm for diabetic wounds by gelling the SIS and loading QCT for slow drug release.
- Open Access
- 1 April 2022
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 104-B (4) , 486-494
Development and validation of a prognostic nomogram for open elbow arthrolysis
Aims: The aim of this study was to develop and internally validate a prognostic nomogram to predict the probability of gaining a functional range of motion (ROM ≥ 120°) after open arthrolysis of the elbow in patients with post-traumatic stiffness of the elbow. Methods: We developed the Shanghai Prediction Model for Elbow Stiffness Surgical Outcome (SPESSO) based on a dataset of 551 patients who underwent open arthrolysis of the elbow in four institutions. Demographic and clinical characteristics were collected from medical records. The least absolute shrinkage and selection operator regression model was used to optimize the selection of relevant features. Multivariable logistic regression analysis was used to build the SPESSO. Its prediction performance was evaluated using the concordance index (C-index) and a calibration graph. Internal validation was conducted using bootstrapping validation. Results: BMI, the duration of stiffness, the preoperative ROM, the preoperative intensity of pain, and grade of post-traumatic osteoarthritis of the elbow were identified as predictors of outcome and incorporated to construct the nomogram. SPESSO displayed good discrimination with a C-index of 0.73 (95% confidence interval 0.64 to 0.81). A high C-index value of 0.70 could still be reached in the interval validation. The calibration graph showed good agreement between the nomogram prediction and the outcome. Conclusion: The newly developed SPESSO is a valid and convenient model which can be used to predict the outcome of open arthrolysis of the elbow. It could assist clinicians in counselling patients regarding the choice and expectations of treatment. Cite this article: Bone Joint J 2022;104-B(4):486–494.
- 1 April 2022
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 104-B (4) , 486-494
Open AccessDevelopment and validation of a prognostic nomogram for open elbow arthrolysis
Aims: The aim of this study was to develop and internally validate a prognostic nomogram to predict the probability of gaining a functional range of motion (ROM ≥ 120°) after open arthrolysis of the elbow in patients with post-traumatic stiffness of the elbow. Methods: We developed the Shanghai Prediction Model for Elbow Stiffness Surgical Outcome (SPESSO) based on a dataset of 551 patients who underwent open arthrolysis of the elbow in four institutions. Demographic and clinical characteristics were collected from medical records. The least absolute shrinkage and selection operator regression model was used to optimize the selection of relevant features. Multivariable logistic regression analysis was used to build the SPESSO. Its prediction performance was evaluated using the concordance index (C-index) and a calibration graph. Internal validation was conducted using bootstrapping validation. Results: BMI, the duration of stiffness, the preoperative ROM, the preoperative intensity of pain, and grade of post-traumatic osteoarthritis of the elbow were identified as predictors of outcome and incorporated to construct the nomogram. SPESSO displayed good discrimination with a C-index of 0.73 (95% confidence interval 0.64 to 0.81). A high C-index value of 0.70 could still be reached in the interval validation. The calibration graph showed good agreement between the nomogram prediction and the outcome. Conclusion: The newly developed SPESSO is a valid and convenient model which can be used to predict the outcome of open arthrolysis of the elbow. It could assist clinicians in counselling patients regarding the choice and expectations of treatment. Cite this article: Bone Joint J 2022;104-B(4):486–494.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi103
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)
Background: ABT-414 is a first-in-class ADC that selectively targets EGFR amplification (amp) to deliver a potent microtubule cytotoxin (monomethyl auristatin F) inside the tumor cells. Almost 50% of GBMs harbor EGFR amp. ABT-414 monotherapy has shown preliminary efficacy in EGFR amp rGBM. Here we report safety and efficacy of ABT-414 + TMZ in EGFR amp rGBM at the recommended phase 2 dose.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi103
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)
Background: ABT-414 is a first-in-class ADC that selectively targets EGFR amplification (amp) to deliver a potent microtubule cytotoxin (monomethyl auristatin F) inside the tumor cells. Almost 50% of GBMs harbor EGFR amp. ABT-414 monotherapy has shown preliminary efficacy in EGFR amp rGBM. Here we report safety and efficacy of ABT-414 + TMZ in EGFR amp rGBM at the recommended phase 2 dose.
- Open Access
- 3 October 2015
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 76 (5) , 1063-1072
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib plus carboplatin and paclitaxel, and assess pharmacokinetics (PK), tolerability, and preliminary efficacy in Japanese patients with solid tumors.
- 3 October 2015
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 76 (5) , 1063-1072
Open AccessA phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib plus carboplatin and paclitaxel, and assess pharmacokinetics (PK), tolerability, and preliminary efficacy in Japanese patients with solid tumors.
- 20 June 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18_suppl) , 9557
The pharmacokinetics (PK) and pharmacodynamics (PD) of ABT-751 in children with recurrent neuroblastoma or other solid tumors
9557 Background: ABT-751 is an orally administered agent that binds to the colchicine site on β-tubulin and blocks microtubule formation. We studied the PK and PD of ABT-751 and its sulfate and glucuronide conjugates in children enrolled on a phase 1 trial in solid tumors and a pilot study in neuroblastoma. Methods: Seventy-two children (2–18 yrs) received ABT-751 on a once, daily × 7d or daily × 21d schedule. Sixty had PK plasma sampling (53 sets analyzed), and 41 had a 24h urine collection after the first dose. Drug concentrations were quantified with a LC/MS/MS assay. Results: Median (range) plasma PK parameters are shown in the table. ABT-751 was rapidly absorbed (Tmax , 2h), and the Cmax and AUC0-8 increased in proportion to dose. The median molar ratio of the sulfate plasma AUC0-8 to glucuronide plasma AUC0-8 was 1.5. The median (range) percent of the administered dose excreted in urine as ABT-751, glucuronide, or sulfate conjugates was 0.09 (0–0.4)%, 10.2 (1.0–38.5)%, and 12.6 (2.3–50.9)%, respectively. The median ABT-751 AUC0-8 was higher in patients with dose-limiting toxicity (DLT) compared to those without DLT on the 7d (118 vs. 74.5 μg·h/mL; P=0.014) and 21d (73.8 vs 49.3 μg·h/mL; P=0.049) schedules. In 28 patients with neuroblastoma, the AUC0-8 did not correlate with time to progression. Apparent clearance (CL/F) did not correlate with age or gender. Conclusions: PK samples were obtained from 83% (60/72) of children enrolled. The ABT-751 AUC0-8 was dose proportional; inter- and intra-patient variability was low. Patients who experienced DLT had higher ABT-751 AUC0-8. The mean CL/F of ABT-751 was similar to that observed in adults (40 mL/min/m2) but did not correlate with age or gender. The sulfate conjugate was the primary metabolite in plasma and urine. Urinary excretion was not a major route of elimination of the parent drug. No significant financial relationships to disclose.
- 20 June 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18_suppl) , 9557
The pharmacokinetics (PK) and pharmacodynamics (PD) of ABT-751 in children with recurrent neuroblastoma or other solid tumors
9557 Background: ABT-751 is an orally administered agent that binds to the colchicine site on β-tubulin and blocks microtubule formation. We studied the PK and PD of ABT-751 and its sulfate and glucuronide conjugates in children enrolled on a phase 1 trial in solid tumors and a pilot study in neuroblastoma. Methods: Seventy-two children (2–18 yrs) received ABT-751 on a once, daily × 7d or daily × 21d schedule. Sixty had PK plasma sampling (53 sets analyzed), and 41 had a 24h urine collection after the first dose. Drug concentrations were quantified with a LC/MS/MS assay. Results: Median (range) plasma PK parameters are shown in the table. ABT-751 was rapidly absorbed (Tmax , 2h), and the Cmax and AUC0-8 increased in proportion to dose. The median molar ratio of the sulfate plasma AUC0-8 to glucuronide plasma AUC0-8 was 1.5. The median (range) percent of the administered dose excreted in urine as ABT-751, glucuronide, or sulfate conjugates was 0.09 (0–0.4)%, 10.2 (1.0–38.5)%, and 12.6 (2.3–50.9)%, respectively. The median ABT-751 AUC0-8 was higher in patients with dose-limiting toxicity (DLT) compared to those without DLT on the 7d (118 vs. 74.5 μg·h/mL; P=0.014) and 21d (73.8 vs 49.3 μg·h/mL; P=0.049) schedules. In 28 patients with neuroblastoma, the AUC0-8 did not correlate with time to progression. Apparent clearance (CL/F) did not correlate with age or gender. Conclusions: PK samples were obtained from 83% (60/72) of children enrolled. The ABT-751 AUC0-8 was dose proportional; inter- and intra-patient variability was low. Patients who experienced DLT had higher ABT-751 AUC0-8. The mean CL/F of ABT-751 was similar to that observed in adults (40 mL/min/m2) but did not correlate with age or gender. The sulfate conjugate was the primary metabolite in plasma and urine. Urinary excretion was not a major route of elimination of the parent drug. No significant financial relationships to disclose.